ZBIO: Obexelimab nears FDA decision as pipeline advances and market research signals strong adoption
Significant financial strength supports a robust pipeline, with obexelimab poised for potential FDA approval and launch in IgG4-RD. Market research indicates strong front-line adoption, and multiple late- and early-stage programs are advancing, with key data readouts expected by year-end.Based on Z…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.